BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Caselli M, Zullo A, Maconi G, Parente F, Alvisi V, Casetti T, Sorrentino D, Gasbarrini G. “Cervia II Working Group Report 2006”: guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis. 2007;39:782-789. [PMID: 17606419 DOI: 10.1016/j.dld.2007.05.016] [Cited by in Crossref: 67] [Cited by in F6Publishing: 77] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut. 2007;56:1353-1357. [PMID: 17566020 DOI: 10.1038/gut.2007.125658] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Cardaropoli S, Rolfo A, Todros T. Helicobacter pylori and pregnancy-related disorders. World J Gastroenterol 2014; 20(3): 654-664 [PMID: 24574739 DOI: 10.3748/wjg.v20.i3.654] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
3 Su P, Li Y, Li H, Zhang J, Lin L, Wang Q, Guo F, Ji Z, Mao J, Tang W, Shi Z, Shao W, Zhu X, Zhang X, Tong Y, Tu H, Jiang M, Wang Z, Jin F, Yang N. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter. 2013;18:274-279. [PMID: 23418857 DOI: 10.1111/hel.12046] [Cited by in Crossref: 96] [Cited by in F6Publishing: 97] [Article Influence: 10.7] [Reference Citation Analysis]
4 Gisbert JP, Calvet X, O'connor JA, Mégraud F, O'morain CA. The sequential therapy regimen for Helicobacter pylori eradication. Expert Opinion on Pharmacotherapy 2010;11:905-18. [DOI: 10.1517/14656561003657152] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
5 Caro SD, Fini L, Daoud Y, Grizzi F, Gasbarrini A, Lorenzo AD, Renzo LD, McCartney S, Bloom S. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J Gastroenterol 2012; 18(40): 5669-5678 [PMID: 23155306 DOI: 10.3748/wjg.v18.i40.5669] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
6 Park HG, Jung MK, Jung JT, Kwon JG, Kim EY, Seo HE, Lee JH, Yang CH, Kim ES, Cho KB. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. Aliment Pharmacol Ther. 2012;35:56-65. [PMID: 22066530 DOI: 10.1111/j.1365-2036.2011.04902.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 5.5] [Reference Citation Analysis]
7 Zullo A, Hassan C, Andriani A, Cristofari F, Bassanelli C, Spinelli GP, Tomao S, Morini S. Treatment of low-grade gastric MALT-lymphoma unresponsive to Helicobacter pylori therapy: a pooled-data analysis. Med Oncol. 2010;27:291-295. [PMID: 19308737 DOI: 10.1007/s12032-009-9207-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
8 Efrati C, Nicolini G, Cannaviello C, O’Sed NP, Valabrega S. Helicobacter pylori eradication: Sequential therapy and Lactobacillus reuteri supplementation. World J Gastroenterol 2012; 18(43): 6250-6254 [PMID: 23180945 DOI: 10.3748/wjg.v18.i43.6250] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
9 Santos IS, Boccio J, Davidsson L, Hernandez-Triana M, Huanca-Sardinas E, Janjetic M, Moya-Camarena SY, Paez-Valery MC, Ruiz-Alvarez V, Valencia ME, Valle NC, Vargas-Pinto G, Solano L, Thomas J. Helicobacter pylori is not associated with anaemia in Latin America: results from Argentina, Brazil, Bolivia, Cuba, Mexico and Venezuela. Public Health Nutr 2009;12:1862-70. [PMID: 19257919 DOI: 10.1017/S1368980009004789] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
10 Gisbert JP, Calvet X, O’Connor A, Mégraud F, O’Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol. 2010;44:313-325. [PMID: 20054285 DOI: 10.1097/mcg.0b013e3181c8a1a3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 61] [Article Influence: 3.0] [Reference Citation Analysis]
11 Zullo A, Esposito G, Ridola L, Hassan C, Lahner E, Perri F, Bianco MA, De Francesco V, Buscarini E, Di Giulio E. Prevalence of lesions detected at upper endoscopy: an Italian survey. Eur J Intern Med. 2014;25:772-776. [PMID: 25245606 DOI: 10.1016/j.ejim.2014.08.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
12 Ciccaglione AF, Cellini L, Grossi L, Marzio L. Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pyloriWorld J Gastroenterol 2012; 18(32): 4386-4390 [PMID: 22969203 DOI: 10.3748/wjg.v18.i32.4386] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
13 McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J, Calvet X, de la Coba C, Montoro M, Bory F, Perez-Aisa A, Forné M, Gisbert JP; Participant Centres. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014;63:244-9. [PMID: 23665990 DOI: 10.1136/gutjnl-2013-304820] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 11.4] [Reference Citation Analysis]
14 Kadayifci A, Uygun A, Kilciler G, Kantarcioglu M, Kara M, Ozcan A, Emer O. Low efficacy of clarithromycin including sequential regimens for Helicobacter pylori infection. Helicobacter. 2012;17:121-126. [PMID: 22404442 DOI: 10.1111/j.1523-5378.2011.00924.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
15 Sacco F, Spezzaferro M, Amitrano M, Grossi L, Manzoli L, Marzio L. Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment. Digestive and Liver Disease 2010;42:110-4. [DOI: 10.1016/j.dld.2009.05.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
16 Zullo A, Severi C, Vannella L, Hassan C, Sbrozzi-Vanni A, Annibale B. Role of gastritis pattern on Helicobacter pylori eradication. Intern Emerg Med. 2012;7:517-522. [PMID: 22105372 DOI: 10.1007/s11739-011-0730-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
17 Hershko C, Camaschella C. How I treat unexplained refractory iron deficiency anemia. Blood. 2014;123:326-333. [PMID: 24215034 DOI: 10.1182/blood-2013-10-512624] [Cited by in Crossref: 84] [Cited by in F6Publishing: 67] [Article Influence: 9.3] [Reference Citation Analysis]
18 Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23-34. [PMID: 22457599 DOI: 10.2147/ceg.s25419] [Cited by in Crossref: 90] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
19 Park JY, Forman D, Greenberg ER, Herrero R. Helicobacter pylori eradication in the prevention of gastric cancer: are more trials needed? Curr Oncol Rep. 2013;15:517-525. [PMID: 24101366 DOI: 10.1007/s11912-013-0341-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
20 Buscarini E, Conte D, Cannizzaro R, Bazzoli F, De Boni M, Delle Fave G, Farinati F, Ravelli P, Testoni PA, Lisiero M. White paper of Italian Gastroenterology: delivery of services for digestive diseases in Italy: weaknesses and strengths. Dig Liver Dis. 2014;46:579-589. [PMID: 24913902 DOI: 10.1016/j.dld.2014.02.019] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
21 Zullo A, Cristofari F, Bragazzi MC, Hassan C. Helicobacter pylori in immigrants: a “foreign” bacterium? Intern Emerg Med 2011;6:7-8. [DOI: 10.1007/s11739-010-0477-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
22 Ren L, Lu H, Li HY, Zhu LY, Xu XQ, Gu LY, Ge ZZ, Li XB. New dual therapy for primary treatment of Helicobacter pylori infection: A prospective randomized study in Shanghai, China. J Dig Dis. 2014;15:622-627. [PMID: 25205201 DOI: 10.1111/1751-2980.12186] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
23 Gisbert JP. “Rescue” regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008; 14(35): 5385-5402 [PMID: 18803350 DOI: 10.3748/wjg.14.5385] [Cited by in CrossRef: 79] [Cited by in F6Publishing: 77] [Article Influence: 5.6] [Reference Citation Analysis]
24 Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007;56:1353-7. [PMID: 17566020 DOI: 10.1136/gut.2007.125658] [Cited by in Crossref: 205] [Cited by in F6Publishing: 191] [Article Influence: 13.7] [Reference Citation Analysis]
25 Zullo A, Hassan C, Ridola L, De Francesco V, Vaira D. Standard triple and sequential therapies for Helicobacter pylori eradication: an update. Eur J Intern Med. 2013;24:16-19. [PMID: 22877993 DOI: 10.1016/j.ejim.2012.07.006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
26 Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao S, Tan HJ, Wu C, Jung HC, Hoang BH, Kachintorn U, Goh K, Chiba T, Rani AA. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. Journal of Gastroenterology and Hepatology 2009;24:1587-600. [DOI: 10.1111/j.1440-1746.2009.05982.x] [Cited by in Crossref: 357] [Cited by in F6Publishing: 353] [Article Influence: 27.5] [Reference Citation Analysis]
27 Zullo A, Ridola L, Hassan C, Bruzzese V, Papini F, Vaira D. Glaucoma and Helicobacter pylori: Eyes wide shut? Digestive and Liver Disease 2012;44:627-8. [DOI: 10.1016/j.dld.2012.03.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
28 De Francesco V, Hassan C, Ridola L, Giorgio F, Ierardi E, Zullo A. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol. 2014;63:748-752. [PMID: 24586031 DOI: 10.1099/jmm.0.072322-0] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 7.3] [Reference Citation Analysis]
29 Hajiani E, Alavinejad P, Avandi N, Masjedizadeh AR, Shayesteh AA. Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial. Middle East J Dig Dis 2018;10:242-8. [PMID: 31049172 DOI: 10.15171/mejdd.2018.117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
30 Witkowska M, Smolewski P. Helicobacter pylori infection, chronic inflammation, and genomic transformations in gastric MALT lymphoma. Mediators Inflamm 2013;2013:523170. [PMID: 23606792 DOI: 10.1155/2013/523170] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
31 Gisbert JP, Gisbert JL, Marcos S, Jimenez-Alonso I, Moreno-Otero R, Pajares JM. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther. 2008;27:346-354. [PMID: 17999716 DOI: 10.1111/j.1365-2036.2007.03573.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 4.0] [Reference Citation Analysis]
32 Gisbert JP. Second-line rescue therapy of helicobacter pylori infection. Therap Adv Gastroenterol. 2009;2:331-356. [PMID: 21180581 DOI: 10.1177/1756283x09347109] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
33 Wang B, Wang YH, Lv ZF, Xiong HF, Wang H, Yang Y, Xie Y. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter. 2015;20:79-88. [PMID: 25381839 DOI: 10.1111/hel.12180] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
34 Selgrad M, Bornschein J, Malfertheiner P. Guidelines for treatment of Helicobacter pylori in the East and West. Expert Rev Anti Infect Ther. 2011;9:581-588. [PMID: 21819326 DOI: 10.1586/eri.11.80] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
35 Zullo A, Hassan C, Oliveti D, Chiriatti A, Chiuri DA, Marotti G, Morelli L, Morini S. Helicobacter pylori management in non-steroidal anti-inflammatory drug therapy patients in primary care. Intern Emerg Med 2012;7:331-5. [PMID: 21451987 DOI: 10.1007/s11739-011-0578-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
36 Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35:209-221. [PMID: 22129228 DOI: 10.1111/j.1365-2036.2011.04937.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 113] [Article Influence: 10.5] [Reference Citation Analysis]
37 Xiao SP, Gu M, Zhang GX. Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori A systematic review and meta-analysis. Scand J Gastroenterol. 2014;49:528-538. [PMID: 24611790 DOI: 10.3109/00365521.2014.887765] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
38 Zullo A, Fiorini G, Bassotti G, Bachetti F, Monica F, Macor D, Paoluzi OA, Scaccianoce G, Portincasa P, De Francesco V, Lorenzetti R, Saracino IM, Pavoni M, Vaira D. Upper Endoscopy in Patients with Extra-Oesophageal Reflux Symptoms: A Multicentre Study. GE Port J Gastroenterol 2020;27:312-7. [PMID: 32999903 DOI: 10.1159/000505581] [Reference Citation Analysis]
39 Roccarina D, Franceschi F, Zocco MA, Garcovich M, Gasbarrini G, Gasbarrini A. Different Antibiotic No Culture Eradicating (DANCE) strategy: an easy way to manage H. pylori eradication. Dig Liver Dis 2012;44:889-92. [PMID: 22743557 DOI: 10.1016/j.dld.2012.05.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
40 Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther. 2011;34:1255-1268. [PMID: 22017749 DOI: 10.1111/j.1365-2036.2011.04887.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 7.2] [Reference Citation Analysis]
41 De Francesco V, Ierardi E, Hassan C, Zullo A. Helicobacter pylori therapy: Present and future. World J Gastrointest Pharmacol Ther 2012; 3(4): 68-73 [PMID: 22966485 DOI: 10.4292/wjgpt.v3.i4.68] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
42 Zullo A, Hassan C, Andriani A, Cristofari F, De Francesco V, Ierardi E, Tomao S, Morini S, Vaira D. Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. Am J Gastroenterol 2009;104:1932-7; quiz 1938. [PMID: 19532131 DOI: 10.1038/ajg.2009.314] [Cited by in Crossref: 59] [Cited by in F6Publishing: 43] [Article Influence: 4.5] [Reference Citation Analysis]
43 Manfredi M, Bizzarri B, de’Angelis GL. Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate. Helicobacter. 2012;17:246-253. [PMID: 22759323 DOI: 10.1111/j.1523-5378.2012.00945.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
44 Trespalacios-Rangél AA, Otero W, Arévalo-Galvis A, Poutou-Piñales RA, Rimbara E, Graham DY. Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014). PLoS One 2016;11:e0160007. [PMID: 27454429 DOI: 10.1371/journal.pone.0160007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
45 Roesler BM, Costa SC, Zeitune JM. Eradication Treatment of Helicobacter pylori Infection: Its Importance and Possible Relationship in Preventing the Development of Gastric Cancer. ISRN Gastroenterol. 2012;2012:935410. [PMID: 22778979 DOI: 10.5402/2012/935410] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
46 Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009;104:21-5. [PMID: 19098844 DOI: 10.1038/ajg.2008.87] [Cited by in Crossref: 88] [Cited by in F6Publishing: 87] [Article Influence: 6.8] [Reference Citation Analysis]
47 Zullo A, Hassan C, Cristofari F, Andriani A, De Francesco V, Ierardi E, Tomao S, Stolte M, Morini S, Vaira D. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 2010;8:105-110. [PMID: 19631287 DOI: 10.1016/j.cgh.2009.07.017] [Cited by in Crossref: 168] [Cited by in F6Publishing: 143] [Article Influence: 12.9] [Reference Citation Analysis]
48 Andriani A, Miedico A, Tedeschi L, Patti C, Di Raimondo F, Leone M, Schinocca L, Romanelli A, Bonanno G, Linea C, Giustini M, Hassan C, Cottone M, Zullo A. Management and long-term follow-up of early stage H. pylori-associated gastric MALT-lymphoma in clinical practice: an Italian, multicentre study. Dig Liver Dis 2009;41:467-73. [PMID: 18945654 DOI: 10.1016/j.dld.2008.09.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
49 Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther. 2011;34:604-617. [PMID: 21745241 DOI: 10.1111/j.1365-2036.2011.04770.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 104] [Article Influence: 10.5] [Reference Citation Analysis]
50 Manfredi M, Bizzarri B, Sacchero RI, Maccari S, Calabrese L, Fabbian F, De'Angelis GL. Helicobacter pylori infection in clinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy. Helicobacter. 2012;17:254-263. [PMID: 22759324 DOI: 10.1111/j.1523-5378.2012.00944.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
51 Zullo A, Hassan C, Andriani A, Cristofari F, Cardinale V, Spinelli GP, Tomao S, Morini S. Primary low-grade and high-grade gastric MALT-lymphoma presentation. J Clin Gastroenterol. 2010;44:340-344. [PMID: 19745757 DOI: 10.1097/mcg.0b013e3181b4b1ab] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
52 Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D. Cumulative H. pylori Eradication Rates in Clinical Practice by Adopting First- and Second-Line Regimens Proposed by the Maastricht III Consensus and a Third-Line Empirical Regimen. The American Journal of Gastroenterology 2008. [DOI: 10.1111/j.1572-0241.2008.02120.x] [Reference Citation Analysis]
53 Assem M, El Azab G, Rasheed MA, Abdelfatah M, Shastery M. Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study. European Journal of Internal Medicine 2010;21:310-4. [DOI: 10.1016/j.ejim.2010.05.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
54 Zullo A, Hassan C, Cristofari F, Perri F, Morini S. Gastric low-grade mucosal-associated lymphoid tissue-lymphoma: Helicobacter pylori and beyond. World J Gastrointest Oncol 2010; 2(4): 181-186 [PMID: 21160595 DOI: 10.4251/wjgo.v2.i4.181] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
55 Ciccaglione AF, Cellini L, Grossi L, Manzoli L, Marzio L. A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study. Helicobacter. 2015;20:390-396. [PMID: 25801708 DOI: 10.1111/hel.12209] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
56 Rollan A, Arab JP, Camargo MC, Candia R, Harris P, Ferreccio C, Rabkin CS, Gana JC, Cortés P, Herrero R, Durán L, García A, Toledo C, Espino A, Lustig N, Sarfatis A, Figueroa C, Torres J, Riquelme A. Management of Helicobacter pylori infection in Latin America: A Delphi technique-based consensus. World J Gastroenterol 2014; 20(31): 10969-10983 [PMID: 25152601 DOI: 10.3748/wjg.v20.i31.10969] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
57 Adamopoulos AB, Stergiou GS, Sakizlis GN, Tiniakos DG, Nasothimiou EG, Sioutis DK, Achimastos AD. Diagnostic value of rapid urease test and urea breath test for Helicobacter pylori detection in patients with Billroth II gastrectomy: a prospective controlled trial. Dig Liver Dis. 2009;41:4-8. [PMID: 18606579 DOI: 10.1016/j.dld.2008.05.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
58 Gisbert JP, Calvet X. Review article: common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphoma. Aliment Pharmacol Ther. 2011;34:1047-1062. [PMID: 21919927 DOI: 10.1111/j.1365-2036.2011.04839.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
59 Guo Q, Guo S, Zhang Y. Treatment of gastric MALT lymphoma with a focus on Helicobacter pylori eradication. Int J Hematol 2013;97:735-42. [PMID: 23616223 DOI: 10.1007/s12185-013-1348-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
60 Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther. 2009;34:41-53. [PMID: 19125902 DOI: 10.1111/j.1365-2710.2008.00969.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 77] [Article Influence: 6.1] [Reference Citation Analysis]
61 Gokcan H, Oztas E, Onal IK. Different bismuth-based therapies for eradicating Helicobacter pylori: Randomized clinical trial of efficacy and safety. Clin Res Hepatol Gastroenterol 2016;40:124-31. [PMID: 26186880 DOI: 10.1016/j.clinre.2015.06.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
62 Molina-infante J, Pazos-pacheco C, Vinagre-rodriguez G, Perez-gallardo B, Dueñas-sadornil C, Hernandez-alonso M, Gonzalez-garcia G, Mateos-rodriguez JM, Fernandez-bermejo M, Gisbert JP. Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple Therapy for Clarithromycin-Susceptible Helicobacter pylori and versus Sequential Therapy for Clarithromycin-Resistant Strains: Nonbismuth Quadruple Concomitant Therapy for Helicobacter pylori infection. Helicobacter 2012;17:269-76. [DOI: 10.1111/j.1523-5378.2012.00947.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 5.6] [Reference Citation Analysis]
63 O'connor A, Gisbert J, O’morain C. Treatment of Helicobacter pylori Infection. Helicobacter 2009;14:46-51. [DOI: 10.1111/j.1523-5378.2009.00704.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
64 Lee JW, Kim N, Kim JM, Nam RH, Chang H, Kim JY, Shin CM, Park YS, Lee DH, Jung HC. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter. 2013;18:206-214. [PMID: 23241101 DOI: 10.1111/hel.12031] [Cited by in Crossref: 172] [Cited by in F6Publishing: 145] [Article Influence: 17.2] [Reference Citation Analysis]
65 Campuzano-Maya G. Hematologic manifestations of Helicobacter pylori infection. World J Gastroenterol 2014; 20(36): 12818-12838 [PMID: 25278680 DOI: 10.3748/wjg.v20.i36.12818] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
66 Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract. 2012;2012:757926. [PMID: 22778723 DOI: 10.1155/2012/757926.Epub2012Jun19] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Shirin H, Leja M, Niv Y. Helicobacter pylori and Non-malignant Diseases. Helicobacter 2008;13:23-7. [DOI: 10.1111/j.1523-5378.2008.00635.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
68 Selgrad M, Malfertheiner P. Treatment of Helicobacter pylori: . Current Opinion in Gastroenterology 2011;27:565-70. [DOI: 10.1097/mog.0b013e32834bb818] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
69 Pontone S, Standoli M, Angelini R, Pontone P. Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice. Dig Liver Dis. 2010;42:541-543. [PMID: 20061196 DOI: 10.1016/j.dld.2009.12.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
70 Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter  pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract 2012;2012:757926. [PMID: 22778723 DOI: 10.1155/2012/757926] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
71 Zullo A, Hassan C, Trapani S, Tammaro G. Rapid urease test for H. pylori diagnosis: pros and cons. Intern Emerg Med 2010;5:257-8. [DOI: 10.1007/s11739-010-0399-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
72 Park JB, Koo JS. Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol 2014; 20(11): 2751-2759 [PMID: 24659867 DOI: 10.3748/wjg.v20.i11.2751] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
73 Iwamoto A, Tanahashi T, Okada R, Yoshida Y, Kikuchi K, Keida Y, Murakami Y, Yang L, Yamamoto K, Nishiumi S, Yoshida M, Azuma T. Whole-genome sequencing of clarithromycin resistant Helicobacter pylori characterizes unidentified variants of multidrug resistant efflux pump genes. Gut Pathog. 2014;6:27. [PMID: 24995043 DOI: 10.1186/1757-4749-6-27] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
74 Yilmaz O. Progress in developing accurate tests for the diagnosis of Helicobacter pylori infection. Expert Opin Med Diagn 2007;1:531-40. [PMID: 23496359 DOI: 10.1517/17530059.1.4.531] [Reference Citation Analysis]
75 Talebi Bezmin Abadi A. Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance 2017;8:123-30. [DOI: 10.1016/j.jgar.2016.11.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
76 Zagari RM, Romano M, Ojetti V, Stockbrugger R, Gullini S, Annibale B, Farinati F, Ierardi E, Maconi G, Rugge M, Calabrese C, Di Mario F, Luzza F, Pretolani S, Savio A, Gasbarrini G, Caselli M. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. Dig Liver Dis. 2015;47:903-912. [PMID: 26253555 DOI: 10.1016/j.dld.2015.06.010] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 10.0] [Reference Citation Analysis]
77 Buri L, Zullo A, Hassan C, Bersani G, Anti M, Bianco MA, Cipolletta L, Giulio ED, Matteo GD, Familiari L, Ficano L, Loriga P, Morini S, Pietropaolo V, Zambelli A, Grossi E, Tessari F, Intraligi M, Buscema M; and the SIED Appropriateness Working Group. Upper GI endoscopy in elderly patients: predictive factors of relevant endoscopic findings. Intern Emerg Med 2013;8:141-6. [DOI: 10.1007/s11739-011-0598-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
78 Buzás GM. Fate of meta-analyses: The case of Helicobacter pyloriWorld J Meta-Anal 2015; 3(1): 20-25 [DOI: 10.13105/wjma.v3.i1.20] [Reference Citation Analysis]
79 Vaira D, Zullo A, Hassan C, Fiorini G, Vakil N. Sequential Therapy for Helicobacter Pylori Eradication: The Time is Now! Therap Adv Gastroenterol. 2009;2:317-322. [PMID: 21180579 DOI: 10.1177/1756283x09343326] [Cited by in Crossref: 34] [Cited by in F6Publishing: 14] [Article Influence: 3.1] [Reference Citation Analysis]